You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Fig. 1

Binding and blocking properties of LY3300054. Panels a-c: 96-well plates were coated with recombinant human (a), cynomolgus (b), or murine (c) PD-L1-Fc fusion protein (100 ng/well each). Bound LY3300054 was detected using HRP-conjugated anti-human Fab antibody and addition of chromogenic substrate (OD at 450nm). 96-well plates were coated with 100 ng/well of recombinant PD-1 (d) or B7-1 protein (e), then incubated with a mixture of biotin-conjugated PD-L1 and either LY3300054 or human IgG1 antibodies. Plate bound PD-L1 was detected using HRP-conjugated streptavidin and addition of chromogenic substrate (OD at 450 nm). In all experiments, each data point is the average of two replicates. Data (a-e) are representative of multiple independent experiments

Back to article page